Voyager Therapeutics (NASDAQ:VYGR) Now Covered by Guggenheim

Guggenheim initiated coverage on shares of Voyager Therapeutics (NASDAQ:VYGR) in a report released on Tuesday morning, MarketBeat Ratings reports. The brokerage issued a buy rating and a $22.00 price objective on the stock.

Several other analysts have also issued reports on the stock. StockNews.com raised shares of Voyager Therapeutics from a hold rating to a buy rating in a research report on Saturday, March 9th. Wells Fargo & Company raised shares of Voyager Therapeutics from an equal weight rating to an overweight rating and boosted their price target for the company from $9.00 to $14.00 in a research report on Tuesday, January 2nd. HC Wainwright assumed coverage on shares of Voyager Therapeutics in a report on Tuesday, March 19th. They set a buy rating and a $30.00 target price on the stock. Finally, Citigroup assumed coverage on shares of Voyager Therapeutics in a report on Thursday, March 7th. They set a buy rating and a $16.00 target price on the stock. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of Moderate Buy and an average price target of $19.33.

Voyager Therapeutics Stock Performance

Shares of VYGR stock opened at $9.31 on Tuesday. The firm’s 50-day simple moving average is $8.37 and its two-hundred day simple moving average is $7.85. Voyager Therapeutics has a 52 week low of $6.06 and a 52 week high of $14.34. The firm has a market cap of $505.53 million, a price-to-earnings ratio of 3.01 and a beta of 0.96.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings results on Wednesday, February 28th. The company reported $1.25 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.59) by $1.84. Voyager Therapeutics had a net margin of 52.93% and a return on equity of 63.89%. The company had revenue of $90.06 million for the quarter, compared to analyst estimates of $4.95 million. Analysts forecast that Voyager Therapeutics will post -1.64 earnings per share for the current year.

Institutional Investors Weigh In On Voyager Therapeutics

Several institutional investors have recently added to or reduced their stakes in VYGR. Citigroup Inc. purchased a new stake in Voyager Therapeutics during the 1st quarter valued at $186,000. BlackRock Inc. raised its holdings in Voyager Therapeutics by 10.6% in the 1st quarter. BlackRock Inc. now owns 514,155 shares of the company’s stock worth $3,919,000 after purchasing an additional 49,319 shares in the last quarter. Lazard Asset Management LLC raised its holdings in Voyager Therapeutics by 144.7% in the 1st quarter. Lazard Asset Management LLC now owns 17,678 shares of the company’s stock worth $134,000 after purchasing an additional 10,455 shares in the last quarter. Charles Schwab Investment Management Inc. bought a new position in Voyager Therapeutics in the 1st quarter worth $122,000. Finally, Northern Trust Corp raised its holdings in Voyager Therapeutics by 2.2% in the 1st quarter. Northern Trust Corp now owns 79,119 shares of the company’s stock worth $603,000 after purchasing an additional 1,683 shares in the last quarter. Hedge funds and other institutional investors own 48.03% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.